Ensovibep

**Semantic type:** Pharmacologic Substance

**Definition:** A designed ankyrin repeat proteins (DARPin)-based, tri-specific agent composed of three severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein (SP) receptor-binding domain (RBD) binding domains that bind to the same epitope region on the SARS-CoV-2 SP RBD and a human serum albumin (HSA)-binding domain, that can potentially be used for immunization against COVID-19. Upon administration, ensovibep specifically targets and binds to three epitopes in the same SARS-CoV-2 SP RBD region, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to three epitopes of the SARS-CoV-2 SP RBD may decrease the potential for viral escape through mutations. The HSA-binding domain binds to HSA which prolongs the half-life of the agent.

**Synonyms:** - ENSOVIBEP - MP 0420 - MP-0420 - MP0420